Credit: Shutterstock. Ryzumvi is a preservation-free eye drop formulation of phentolamine mesylate, an alpha adrenergic blocker. The Food and Drug Administration (FDA) has approved Ryzumvi™ ...
Please provide your email address to receive an email when new articles are posted on . Significantly more participants treated with phentolamine ophthalmic solution 0.75% vs. placebo achieved ...
Credit: Getty Images. MydCombi is a combination of tropicamide, an anticholinergic, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist. The Food and Drug Administration (FDA) has ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Ryzumvi for the treatment of pharmacologically induced mydriasis. Ryzumvi is expected to be ...
A 3-year-old girl with an unremarkable medical history suddenly developed dilated pupils and trouble walking, according to a case report in JAMA Ophthalmology. The child was brought in to the ...
The FDA has approved phentolamine ophthalmic solution (Ryzumvi) 0.75% for treatment-induced mydriasis, Viatris and Ocuphire Pharma announced. The approval stipulates use of the eye drops to manage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results